Search Result

Results for "

ddI

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (1) Dopamine Receptor (1) HIV (2) Na+/H+ Exchanger (NHE) (2) Reverse Transcriptase (1) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cardiovascular Disease (2) Infection (2) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Didanosine 1 Publications Verification 2',3'-Dideoxyinosine; ddI	HIV Reverse Transcriptase	Infection
Didanosine (2',3'-Dideoxyinosine; ddI) is a a potent and orally active dideoxynucleoside analogue, and also is a potent nucleoside reverse transcriptase inhibitor. Didanosine shows antiretroviral activity for HIV .

ddATP trisodium 2',3'-Dideoxyadenosine 5'-triphosphate trisodium	DNA/RNA Synthesis HIV	Infection
ddATP (2',3'-Dideoxyadenosine 5'-triphosphate) trisodium, an active metabolite of 2',3'-dideoxyinosine, is a chain-elongating inhibitor of DNA polymerase. ddATP trisodium can be used for Sanger method for DNA sequencing and research of virus infection .

DDI1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DDI1 Human Pre-designed siRNA Set A contains three designed siRNAs for DDI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DDI1 Human Pre-designed siRNA Set A DDI1 Human Pre-designed siRNA Set A

DDI2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DDI2 Human Pre-designed siRNA Set A contains three designed siRNAs for DDI2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DDI2 Human Pre-designed siRNA Set A DDI2 Human Pre-designed siRNA Set A

LY3154885	Dopamine Receptor	Neurological Disease
LY3154885 is an orally active dopamine D1 receptor positive allosteric modulator (PAM). LY3154885 has an improved agent-agent interactions (DDI) risk profile .

BI-9627 1 Publications Verification	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC₅₀s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .

BI-9627 hydrochloride 1 Publications Verification	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Name
Email *

	Sorry, but the email address you supplied was invalid.

Inhibitors & Agonists